Drug intelligence / Profile preview

BDB-2

Development stage: Preclinical
Lead developer: Beijing Defengrei Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BDB-2 is an anti-C5a antibody developed by Beijing Defengrei Biotechnology (BDB) and subsequently by its parent company, Staidson. The drug was developed using the vilobelimab cell line, for which InflaRx GmbH granted an exclusive license to BDB for development and commercialization in China. As an anti-C5a antibody, BDB-2 targets the complement component C5a, aiming to modulate the immune response. InflaRx is eligible for mid-single-digit royalties on net sales of BDB-2 in China.

Targets

Complement component C5a

Beyond the preview

Go deeper on BDB-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDB-2.

Explore the full profile